CinCor Pharma, Inc.
CINC · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | -0.23 | -0.05 | 0.00 |
| FCF Yield | -5.44% | -4.63% | -1.18% |
| EV / EBITDA | -12.42 | -17.57 | -70.94 |
| Quality | |||
| ROIC | -34.11% | -105.94% | -49.34% |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.61 | 0.78 | 0.88 |
| Growth | |||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -77.32% | -292.73% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 3.94 | 1.31 | 2.24 |
| Interest Coverage | 0.00 | 0.00 | 0.00 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 |